1. Home
  2. Analysis
  3. Predictions

Personalized prediction for a 56 year old man who takes Moxidectin, Fexinidazole, Oxycodone, Clindamycin Hydrochloride, Flagyl, Praziquantel (an AI-powered real world drug study)

Summary:

This is a personalized prediction of potential side effects and undetected conditions for up to one year, if you would have adverse effects. The study is created by eHealthMe based on data from the FDA.

On Sep, 21, 2025, 6,544,828 related reports were analyzed:

What are the drugs?

What are the conditions?

Potential side effects:

Drug ineffective
  • 5.48% for males aged 56 (±5) who have sinus infection and infection parasitic
  • 5.35% for males aged 56 (±5) who have fascial infection and sinus infection
  • 5.35% for males aged 56 (±5) who have cervical rib syndrome and sinus infection
  • 5.12% for males aged 56 (±5) who take moxidectin
  • 5.12% for males aged 56 (±5) who take fexinidazole
  • 5.12% for males aged 56 (±5) who take oxycodone
  • 5.12% for males aged 56 (±5) who take clindamycin hydrochloride
  • 5.12% for males aged 56 (±5) who take flagyl
  • 5.12% for males aged 56 (±5) who take praziquantel
Dyspnea
  • 5.1% for males aged 56 (±5) who have fascial infection and sinus infection
  • 5.1% for males aged 56 (±5) who have cervical rib syndrome and sinus infection
Fatigue
  • 5.89% for males aged 56 (±5) who have sinus infection and infection parasitic
  • 5.77% for males aged 56 (±5) who have fascial infection and sinus infection
  • 5.77% for males aged 56 (±5) who have cervical rib syndrome and sinus infection
Joint pain
  • 6.52% for males aged 56 (±5) who have fascial infection and sinus infection
  • 6.52% for males aged 56 (±5) who have cervical rib syndrome and sinus infection
  • 6.38% for males aged 56 (±5) who have sinus infection and infection parasitic
Rashes
  • 6.69% for males aged 56 (±5) who have fascial infection and sinus infection
  • 6.69% for males aged 56 (±5) who have cervical rib syndrome and sinus infection
  • 6.55% for males aged 56 (±5) who have sinus infection and infection parasitic
Sinusitis
  • 7.02% for males aged 56 (±5) who have fascial infection and sinus infection
  • 7.02% for males aged 56 (±5) who have cervical rib syndrome and sinus infection
  • 6.87% for males aged 56 (±5) who have sinus infection and infection parasitic
Tendon rupture
  • 8.28% for males aged 56 (±5) who have fascial infection and sinus infection
  • 8.28% for males aged 56 (±5) who have cervical rib syndrome and sinus infection
  • 8.1% for males aged 56 (±5) who have sinus infection and infection parasitic

Potential co-existing conditions:

Asthma
  • 5.69% for males aged 56 (±5) who have cervical rib syndrome and sinus infection
  • 5.69% for males aged 56 (±5) who have fascial infection and sinus infection
  • 5.56% for males aged 56 (±5) who have sinus infection and infection parasitic
High blood cholesterol
  • 5.6% for males aged 56 (±5) who have cervical rib syndrome and sinus infection
  • 5.6% for males aged 56 (±5) who have fascial infection and sinus infection
  • 5.48% for males aged 56 (±5) who have sinus infection and infection parasitic
High blood pressure
  • 10.15% for males aged 56 (±5) who have sinus infection and infection parasitic
  • 9.87% for males aged 56 (±5) who have fascial infection and sinus infection
  • 9.87% for males aged 56 (±5) who have cervical rib syndrome and sinus infection
Sinusitis
  • 100.0% for males aged 56 (±5) who have fascial infection and sinus infection
  • 100.0% for males aged 56 (±5) who have cervical rib syndrome and sinus infection
  • 97.87% for males aged 56 (±5) who have sinus infection and infection parasitic

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

How the study uses the data?

The study is based on gender, age, active ingredients of any drugs used, and more. Other drugs that have the same active ingredients (e.g. generic drugs) are considered.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

Recent personalized studies on eHealthMe:

© 2025 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.